Frontlight ResearchEarly access
CompletedNo phase
Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients
Key facts
- Who runs it
- Methodist Health System
- Where
- Richardson, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 400 people enrolled
- Started
- 17 Nov 2021
- Ended
- 22 Jul 2025
- Type of study
- Observational
- Record updated
- 28 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Effectiveness of intermediate-intensity vs standard prophylactic enoxaparin regimens on preventing DVT and/or PE in patients with COVID-19, measured using the following variables:
- Enoxaparin dose (appropriate for kidney function)
- Charlson comorbidity index (CCI) score
- Padua prediction score for risk of VTE
- IMPROVE [International Medical Prevention Registry on VTE] bleeding risk assessment score
- ICU status
- Number of thromboembolic events
- Length of stay
- Readmissions for DVT and/or PE
- In-hospital mortality with associated DVT or PE
Who cannot take part
- Safety of intermediate-intensity vs standard prophylactic enoxaparin regimens in patients with COVID-19, measured using the following variables:; Bleeding events; Type of bleeding event
Where in United States
- Methodist Richardson Medical CenterRichardson, United States
About the trial
What the trial wants to find out
Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 28 July 2025